PMID- 10362822
OWN - NLM
STAT- MEDLINE
DCOM- 19990610
LR  - 20151119
IS  - 0028-4793 (Print)
IS  - 0028-4793 (Linking)
VI  - 340
IP  - 23
DP  - 1999 Jun 10
TI  - A serologic marker of paraneoplastic limbic and brain-stem encephalitis in
      patients with testicular cancer.
PG  - 1788-95
AB  - BACKGROUND: In patients with cancer, symptoms of limbic and brain-stem
      dysfunction may result from a paraneoplastic disorder. Paraneoplastic limbic or
      brain-stem encephalitis occurs more frequently with testicular cancer than with
      most other cancers. We sought antineuronal antibodies that might be used in a
      diagnostic test for this syndrome. METHODS: Immunohistochemical and
      immunoblotting techniques were used to detect serum and cerebrospinal fluid
      antibodies. Serologic screening of a complementary DNA library and Northern
      blotting were used to clone the target antigen and determine which tissues
      expressed it. RESULTS: Of 13 patients with testicular cancer and paraneoplastic
      limbic or brain-stem encephalitis (or both), 10 had antibodies in serum and
      cerebrospinal fluid against a 40-kd neuronal protein. These antibodies were used 
      to clone a gene that we call Ma2, which codes for a protein (Ma2) that was
      recognized by serum from the 10 patients, but not by serum from 344 control
      subjects. Ma2 was selectively expressed by normal brain tissue and by the
      testicular tumors of the patients. Ma2 shares homology with Ma1, a
      "brain-testis-cancer" gene related to other paraneoplastic syndromes and tumors. 
      CONCLUSIONS: The serum of patients with subacute limbic and brain-stem
      dysfunction and testicular cancer contains antibodies against a protein found in 
      normal brain and in testicular tumors. Detection of these antibodies supports the
      paraneoplastic origin of the neurologic disorder and could be of diagnostic
      importance.
FAU - Voltz, R
AU  - Voltz R
AD  - Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY
      10021, USA.
FAU - Gultekin, S H
AU  - Gultekin SH
FAU - Rosenfeld, M R
AU  - Rosenfeld MR
FAU - Gerstner, E
AU  - Gerstner E
FAU - Eichen, J
AU  - Eichen J
FAU - Posner, J B
AU  - Posner JB
FAU - Dalmau, J
AU  - Dalmau J
LA  - eng
GR  - NS-26064/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antigens)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Complementary)
RN  - 0 (Ma1 antigen)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA, Messenger)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 1999 Jun 10;340(23):1831-3. PMID: 10362830
CIN - N Engl J Med. 1999 Nov 4;341(19):1475-6. PMID: 10577104
MH  - Animals
MH  - Antigens/analysis/genetics/*immunology
MH  - Antigens, Neoplasm/immunology
MH  - Autoantibodies/*blood
MH  - Biomarkers/blood
MH  - Brain Chemistry
MH  - Brain Stem/immunology
MH  - DNA, Complementary/genetics
MH  - Encephalitis/*diagnosis/etiology/immunology
MH  - Female
MH  - Hippocampus/immunology
MH  - Humans
MH  - Limbic System/immunology
MH  - Male
MH  - Nerve Tissue Proteins/analysis/genetics/*immunology
MH  - Paraneoplastic Syndromes/*diagnosis/etiology/immunology
MH  - RNA, Messenger/analysis
MH  - Rats
MH  - Testicular Neoplasms/*complications/immunology/pathology
EDAT- 1999/06/11 00:00
MHDA- 1999/06/11 00:01
CRDT- 1999/06/11 00:00
PHST- 1999/06/11 00:00 [pubmed]
PHST- 1999/06/11 00:01 [medline]
PHST- 1999/06/11 00:00 [entrez]
AID - 10.1056/NEJM199906103402303 [doi]
PST - ppublish
SO  - N Engl J Med. 1999 Jun 10;340(23):1788-95. doi: 10.1056/NEJM199906103402303.